



Ministerie van
Volkshuisvesting, Ruimtelijke
Ordening en Infrastructuur



SARS-CoV-2 re-infection in The Netherlands

(10)(2e)

Medical Microbiology Labs


(10)(2e)

(10)(2e)

(10)(2e)




Age and sex of participants






PCR results of primary and secondary infections





Sequence analysis results of primary and secondary infections





Molecular evidence of re-infection; 7 cases


PCR 1 st date	Ct 1 st	Seq type 1 st	PCR 2 nd date	Ct 2 nd	Seq type 2 nd	days between PCR 1 st and PCR 2 nd
14/04/20	26	B.1.1	26/04/20	26	B.1.1.1	12
12/04/20	15	B.1.78	05/05/20	27	B.2	23
02/04/20	23	B.1.1	09/06/20	31	B.1.1	68
27/03/20	29	B.1.1.47	05/07/20	30	B.1.1	100
15/04/20	31	B.3	10/07/20	30	B.1	87
02/04/20	23	B.1.22	11/07/20	34	B.1.1.47	99
24/04/20	26	B.1.22	14/07/20	20	B.3	81

A dynamic nomenclature proposal for SARS-CoV-2 to assist genomic epidemiology

(10)(2e), (10)(2e)
(10)(2e)




Wantai ratio s of serum samples after secondary infections






Virus neutralization of serum samples after secondary infections





Serological response after re-infection Multiplex Immunoassay (MIA, Luminex)





Serological evidence of re-infection; part 1

days between onset 1 and onset 2	days between onset 2 and serum collection	Wantai ratio	VNT50	IgG (GMC) S1	IgG (GMC) RBD	Ai% S1	Ai% RBD
12	9	24.38	480	2575.05	3063.28	18	35
20	5	0.98	30	2.60	3.95	46	59
64	7	25.24	15	9.67	8.36	51	63
63	4	23.64	560	480.55	1952.06	29	26
82	12	23.52	80	52.76	53.87	55	58
85	6	22.74	30	26.15	19.01	39	48
74	29	27.04	40	38.43	34.38	65	72
88	3	23.53	320	92.93	80.90	50	67
94	2	21.59	160	45.15	51.68	58	68
105	3	0.66	<10	1.14	2.00		
100	-47	18.46	60	5.97	8.56	46	45
115	7	21.38	<10	5.30	5.12	51	59




Serological evidence of re-infection; part 2

days between onset 1 and onset 2	days between onset 2 and serum collection	Wantai ratio	VNT50	IgG (GMC) S1	IgG (GMC) RBD	Ai% S1	Ai% RBD
79	3	0.02					
73	6	23.74	560	198.19	194.86	63	79
84	13	23.95	560	315.52	751.05	57	39
118	12	19.6	40	14.53	20.06	69	57
122	14	21.19	40	13.07	16.42	70	73
74	3	23.44	60	79.46	271.42	47	21
79	6	22.01	80	42.18	61.40	36	48
62	5	23.38	20	17.26	18.05	43	80
57	12	16.86	20	12.17	11.55	41	59
133	19	26.42	40	50.45	40.35	65	69
119	6	11.11	<10	3.74	6.59	36	32
125	1	24	<10	5.63	5.48	62	64
133	7	20.41	15	5.09	8.60	60	45



Serological evidence of re-infection; avidity index





Conclusions

- † Twenty-nine potential re-infection cases investigated by laboratory testing
- † Seven re-infection cases confirmed by sequence analysis
 - Qualitative comparison, not easy to obtain
 - Re-infection with identical virus would not qualify
- † Fourteen re-infection cases confirmed by serological criteria
 - Quantitative criteria:
 - avidity index >50%, <30 days after onset
- † None from the set of 7 occur in the set of 14
- † Four possible re-infection cases; <50% AI, >20 Wantai ratio, <14 days after onset
- † Four are probably not re-infection cases, PCR not confirmed, few samples available, no serological response after onset of symptoms